U.S. court invalidates patent on J&J cancer drug Zytiga
January 17, 2018 at 18:21 PM EST
NEW YORK, Jan 17 (Reuters) - A U.S. administrative court on Wednesday invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions.
